[go: up one dir, main page]

PE20090296A1 - Compuestos derivados de pirimidin-2,4-diona e imidazolin-2,4-diona y composicion farmaceutica que comprende a dichos compuestos para tratar enfermedades mediadas por vih, sida o arc - Google Patents

Compuestos derivados de pirimidin-2,4-diona e imidazolin-2,4-diona y composicion farmaceutica que comprende a dichos compuestos para tratar enfermedades mediadas por vih, sida o arc

Info

Publication number
PE20090296A1
PE20090296A1 PE2008000903A PE2008000903A PE20090296A1 PE 20090296 A1 PE20090296 A1 PE 20090296A1 PE 2008000903 A PE2008000903 A PE 2008000903A PE 2008000903 A PE2008000903 A PE 2008000903A PE 20090296 A1 PE20090296 A1 PE 20090296A1
Authority
PE
Peru
Prior art keywords
diona
compounds
alkyl
hiv
aids
Prior art date
Application number
PE2008000903A
Other languages
English (en)
Inventor
Joshua Kennedy-Smith
Zachary Kevin Sweeney
Jeffrey Wu
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712538&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090296(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20090296A1 publication Critical patent/PE20090296A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/72—Two oxygen atoms, e.g. hydantoin
    • C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
    • C07D233/78—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/553—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms with halogen atoms or nitro radicals directly attached to ring carbon atoms, e.g. fluorouracil

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

REFERIDA A COMPUESTOS DE FORMULA (I), DONDE A ES CHR3=CHR2, CH2R3CH2R2, CH2; R1 ES (II), ALQUILO(C1-C6); R2 ES H, ALQUILO(C1-C3), HALOALQUILO(C1-C3), ALQUENILO(C2-C6), NRaRb, ENTRE OTROS; X1 ES O O S; X2 ES O O SI A ES CHR3=CHR2, X2 ES O O NRd; R3 ES H O ALQUILO (C1-C3); R4 ES HALOGENO, ALQUILO(C1-C6), CICLOALQUILO(C3-C6), HALOALQUILO(C1-C6) O ALCOXI (C1-C6); Ra Y Rb SON H, ALQUILO(C1-C3) O ACILO(C1-C6); Rd ES H, ALQUILO(C1-C3) O ACILO(C1-C6); Ar ES FENILO SUSTITUIDO POR 1 A 3 HALOGENO, CIANO, ALCOXI(C1-C6); n ES DE 1 A 3. SON COMPUESTOS PREFERIDOS: 3-[6-BROMO-3-(2,4-DIOXO-TETRAHIDRO-PIRIMIDIN-1-ILMETIL)-2-FLUOR-FENOXI]-5-CLORO-BENZONITRILO, 3-[3-(4-AMINO-2-OXO-2H-PIRIMIDIN-1-ILMETIL)-6-BROMO-2-FLUOR-FENOXI]-5-CLORO-BENZONITRILO; ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA Y A UN METODO PARA SU PREPARACION. DICHOS COMPUESTOS INHIBEN LA TRANSCRIPTASA INVERSA DEL VIH-1 Y SON UTILES EN LA PREVENCION Y TRATAMIENTO DEL VIH, SIDA Y/O DEL ARC
PE2008000903A 2007-05-30 2008-05-27 Compuestos derivados de pirimidin-2,4-diona e imidazolin-2,4-diona y composicion farmaceutica que comprende a dichos compuestos para tratar enfermedades mediadas por vih, sida o arc PE20090296A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93225107P 2007-05-30 2007-05-30

Publications (1)

Publication Number Publication Date
PE20090296A1 true PE20090296A1 (es) 2009-03-27

Family

ID=39712538

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000903A PE20090296A1 (es) 2007-05-30 2008-05-27 Compuestos derivados de pirimidin-2,4-diona e imidazolin-2,4-diona y composicion farmaceutica que comprende a dichos compuestos para tratar enfermedades mediadas por vih, sida o arc

Country Status (17)

Country Link
US (1) US8026362B2 (es)
EP (1) EP2155692B1 (es)
JP (1) JP5167350B2 (es)
KR (1) KR101542629B1 (es)
CN (1) CN101679294B (es)
AR (1) AR066743A1 (es)
AU (1) AU2008257771B2 (es)
BR (1) BRPI0811645A2 (es)
CA (1) CA2687747C (es)
CL (1) CL2008001537A1 (es)
EA (1) EA016386B1 (es)
ES (1) ES2542153T3 (es)
IL (1) IL202143A (es)
MX (1) MX2009012704A (es)
PE (1) PE20090296A1 (es)
TW (1) TWI425946B (es)
WO (1) WO2008145562A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200901969A (en) * 2007-06-06 2009-01-16 Smithkline Beecham Corp Chemical compounds
DE102008030091B4 (de) * 2008-06-25 2011-03-03 Resprotect Gmbh Uracilderivate und deren Verwendung
CN111936498B (zh) 2018-03-26 2024-04-16 诺华股份有限公司 N-(3-(7H-吡咯并[2,3-d]嘧啶-4-基)苯基)苯甲酰胺衍生物
US11925643B2 (en) 2018-05-23 2024-03-12 Mor Research Applications Ltd. Toll-like receptor 4 (TLR4) inhibitors and use thereof
CN113423695A (zh) 2018-12-18 2021-09-21 默沙东公司 作为针对hiv感染细胞的选择性细胞毒剂的嘧啶酮衍生物
WO2021053495A1 (en) * 2019-09-16 2021-03-25 Novartis Ag Bifunctional degraders and their methods of use

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110470A (en) * 1965-10-07 1978-08-29 Horst Kummer Pharmaceutical composition comprising d,l-α-methyl-thyroxine ethyl ester and the salts thereof and the control of cholesterol and triglyceride blood level therewith
US4949314A (en) 1966-08-16 1990-08-14 The United States Of America As Represented By The Secretary Of The Navy Method and means for increasing echo-ranging-search rate
GB1601310A (en) * 1978-05-23 1981-10-28 Lilly Industries Ltd Aryl hydantoins
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
GB8327880D0 (en) 1983-10-18 1983-11-16 Ajinomoto Kk Saccharomyces cerevisiae
US4604377A (en) 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
US4530787A (en) 1984-03-28 1985-07-23 Cetus Corporation Controlled oxidation of microbially produced cysteine-containing proteins
US4569790A (en) 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
IL76360A0 (en) 1984-09-26 1986-01-31 Takeda Chemical Industries Ltd Mutual separation of proteins
US4752585A (en) 1985-12-17 1988-06-21 Cetus Corporation Oxidation-resistant muteins
US4748234A (en) 1985-06-26 1988-05-31 Cetus Corporation Process for recovering refractile bodies containing heterologous proteins from microbial hosts
AU622926B2 (en) 1988-09-09 1992-04-30 Nippon Kayaku Kabushiki Kaisha Pyrimidine or purine cyclobutane derivatives
US5925643A (en) 1990-12-05 1999-07-20 Emory University Enantiomerically pure β-D-dioxolane-nucleosides
US5489697A (en) 1994-08-03 1996-02-06 Medichem Research, Inc. Method for the preparation of (+)-calanolide A and intermediates thereof
IL117574A0 (en) 1995-04-03 1996-07-23 Bristol Myers Squibb Co Processes for the preparation of cyclobutanone derivatives
US7166730B2 (en) 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MXPA05010081A (es) 2003-03-24 2005-11-23 Hoffmann La Roche Bencil-piridazinonas como inhibidores de transcriptasa inversa.
TW200505441A (en) 2003-03-24 2005-02-16 Hoffmann La Roche Non-nucleoside reverse transcriptase inhibitorsⅠ
JP4107658B2 (ja) 2003-07-23 2008-06-25 インターナショナル・ビジネス・マシーンズ・コーポレーション 分類因子検出装置、分類因子検出方法、プログラム、及び記録媒体
CA2555656C (en) 2004-02-27 2017-03-28 Institut Curie New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis
JP4627315B2 (ja) 2004-03-23 2011-02-09 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としてのベンジルピリダジノン誘導体
JP2007532592A (ja) 2004-04-15 2007-11-15 エフ．ホフマン−ラ　ロシュ　アーゲー ピリダジノン化合物の製造方法
US7625949B2 (en) 2004-04-23 2009-12-01 Roche Palo Alto Llc Methods for treating retroviral infections
US7166738B2 (en) 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
CA2471006A1 (en) * 2004-06-23 2005-12-23 Bayer Inc. Silica reinforced elastomer compounds prepared with dry liquid modifiers
BRPI0513858B8 (pt) * 2004-07-27 2021-05-25 Hoffmann La Roche compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
ATE528001T1 (de) 2004-08-25 2011-10-15 Ardea Biosciences Inc S-triazolyl-alpha-mercaptoacetanilide als inhibitoren von hiv-umkehrtranskriptase
DE602005023360D1 (de) 2004-09-17 2010-10-14 Idenix Pharmaceuticals Inc Phosphoindole als HIV-Inhibitoren
CA2577144C (en) 2004-09-30 2011-06-21 Boehringer Ingelheim International Gmbh Alkynyl compounds as non-nucleoside reverse transcriptase inhibitors
JP4423166B2 (ja) 2004-10-29 2010-03-03 富士通株式会社 電子部品の超音波実装方法および超音波実装装置
EP1831157A2 (en) 2004-12-22 2007-09-12 Pfizer Limited Nonnucleoside inhibitors of hiv-1 reverse transcriptase
EP1863777A1 (en) * 2005-03-24 2007-12-12 F.Hoffmann-La Roche Ag 1,2,4 -triazole-5-one compounds as heterocyclic reverse transcriptase inhibitors
US20060225874A1 (en) 2005-04-11 2006-10-12 Shives Gary D Sandwiched thermal article
AR057455A1 (es) 2005-07-22 2007-12-05 Merck & Co Inc Inhibidores de la transcriptasa reversa de vih y composicion farmaceutica
WO2007039463A1 (en) * 2005-09-30 2007-04-12 F. Hoffmann-La Roche Ag Nnrt inhibitors
ES2320042T3 (es) 2005-10-19 2009-05-18 F. Hoffmann-La Roche Ag Inhibidores de transcriptasa reversa con nucleosidos de n-fenil fenilacetamida.
JP2009515826A (ja) 2005-10-19 2009-04-16 エフ．ホフマン−ラ ロシュ アーゲー フェニル−アセトアミドｎｎｒｔ阻害剤
JP2010530863A (ja) * 2007-06-22 2010-09-16 エフ．ホフマン−ラ ロシュ アーゲー 非ヌクレオシド逆転写酵素阻害剤としての尿素及びカルバマート誘導体

Also Published As

Publication number Publication date
IL202143A0 (en) 2010-06-16
MX2009012704A (es) 2009-12-08
CN101679294B (zh) 2012-08-08
US20090076045A1 (en) 2009-03-19
KR20100028584A (ko) 2010-03-12
AU2008257771B2 (en) 2015-02-19
EA200901599A1 (ru) 2010-06-30
KR101542629B1 (ko) 2015-08-06
CN101679294A (zh) 2010-03-24
JP5167350B2 (ja) 2013-03-21
AU2008257771A1 (en) 2008-12-04
EP2155692A1 (en) 2010-02-24
EP2155692B1 (en) 2015-06-17
CA2687747C (en) 2015-11-17
US8026362B2 (en) 2011-09-27
ES2542153T3 (es) 2015-07-31
TWI425946B (zh) 2014-02-11
JP2010528083A (ja) 2010-08-19
WO2008145562A1 (en) 2008-12-04
BRPI0811645A2 (pt) 2014-11-11
TW200911260A (en) 2009-03-16
AR066743A1 (es) 2009-09-09
EA016386B1 (ru) 2012-04-30
CA2687747A1 (en) 2008-12-04
IL202143A (en) 2014-06-30
CL2008001537A1 (es) 2008-12-05

Similar Documents

Publication Publication Date Title
PE20091000A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20090296A1 (es) Compuestos derivados de pirimidin-2,4-diona e imidazolin-2,4-diona y composicion farmaceutica que comprende a dichos compuestos para tratar enfermedades mediadas por vih, sida o arc
MA31419B1 (fr) Derives de pyridine
MA32965B1 (fr) Derives de sulfonamides
PE20120659A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20090067A1 (es) Inhibidores no nucleosidos de transcriptasa inversa
HN2009001160A (es) Inhibidores de transcriptasa inversa no nucleosidicos
PE20130158A1 (es) Inhibidores no nucleosidicos de la transcriptasa inversa
PE20060777A1 (es) Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
NO20071274L (no) Inhibitorer av hepatitt C virus RNA-avhengig RNA polymerase, og sammensetninger og behandlinger ved anvendelse av samme.
PE20090775A1 (es) Nuevos derivados de biarilo
PE20050013A1 (es) Composiciones farmaceuticas como inhibidores de la proteasa del virus de la hepatitis c
PE20081897A1 (es) 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas
TNSN07022A1 (fr) Derives de pyridine
PE20110875A1 (es) Derivados de isoindol como inhibidores de bace
PE20121479A1 (es) Inhibidores del virus de la hepatitis c
PE20061335A1 (es) Compuestos derivados de benzodioxano y benzodioxolano como moduladores del receptor 5-ht2c
UY29266A1 (es) Compuestos de piridazinona
PE20080702A1 (es) PROLINAMIDAS SUSTITUIDAS COMO INHIBIDORES DEL FACTOR Xa
UY33097A (es) DERIVADOS DE (1h-PIRAZOL-5-IL)UREIDOARILO 1,3-DISUSTITUIDOS Y SUS USOS TERAPÉUTICOS
PE20081375A1 (es) Derivados octahidro-pirrolo[3,4-c]pirrol como antagonistas del receptor ccr5
PE20080734A1 (es) Inhibidores no nucleosidicos de la transcriptasa inversa
PE20090478A1 (es) Compuestos de indol macrociclicos como inhibidores de la proteasa del virus de la hepatitis c
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20040828A1 (es) Benzoxazinonas como modulares de 5-hidroxitriptamina (5-ht)

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed